# US 2025/0127873 A1 · Compositions and methods for prevention of piscine myocarditis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0127873 A1
- Document ID: US20250127873A1
- Status: Published application
- Kind: A1
- Application number: 18/721,719
- Filed: 2022-12-19
- Published: 2025-04-24
- Earliest claimed: 2021-12-20
- Assignees: Zoetis Services LLC
- Applicants: Zoetis Services LLC
- Inventors: Oyvind Haugland; Marius Andre de Feijter Karlsen; Linda Helena Hauge
- Web page: https://patentgrep.com/patent/US20250127873A1

## CPC

- A61K 39/12: Viral antigens
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C07K 14/08: RNA viruses
- C12N 15/625: {containing a sequence coding for a signal sequence}
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K 2039/575: {humoral response}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/02: containing a signal sequence
- C07K 2319/03: containing a transmembrane segment
- C12N 2720/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2720/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are antigens, vaccines, and method for treating fish against infection with Piscine Myocarditis Virus (PMCV)

## Claims

### Claim 1

A protein comprising, from N- to C-terminus:
a. a sequence that is at least 90% identical, or at least 91% identical, or at least 92% identical, or at least 93% identical, or at least 94% identical, or at least 95% identical, or at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical, or 100% identical to SEQ ID NO: 34 or SEQ ID NO: 35, and
b. an amino acid sequence that is at least 95%, 96%, 97%, 98%, 99%, or 100% identical to any one of SEQ ID NOs: 25-33,
wherein,
compared to SEQ ID NO: 1, said protein comprises an internal deletion that is at least four consecutive amino acids long.

### Claim at position 2

2-13. (canceled)

### Claim 14 (depends on 1)

The protein according to claim 1, which includes the sequence that is at least 90% identical to SEQ ID NO: 28, and, optionally lacks SEQ ID NO: 4 or a sequence that is at least 90% identical to SEQ ID NO: 4.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

The protein of claim 1 which a) lacks SEQ ID NO: 3 or a sequence that is at least 90% identical to SEQ ID NO: 3 and/or b) lacks SEQ ID NO: 24 or a sequence that is at least 90% identical to SEQ ID NO: 24.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The protein of claim 1 comprising SEQ ID NO: 30 or a sequence at least 95%, or 96%, or 97% or 98% or 99% identical thereto, and, optionally, lacking SEQ ID NO: 24 or a sequence that is at least 90% identical to SEQ ID NO: 24.

### Claim 20

(canceled)

### Claim 21 (depends on 1)

The protein of claim 1, comprising SEQ ID NO: 31 or a sequence at least 95%, or 96%, or 97% or 98% or 99% identical thereto, and, optionally, which lacks at least one of SEQ ID NO: 3 or SEQ ID NO: 24, or an amino acid sequence that is at least 90% identical to SEQ ID NO: 3 or SEQ ID NO: 24.

### Claim 22

(canceled)

### Claim 23 (depends on 1)

The protein of claim 1, comprising SEQ ID NO: 32 or a sequence at least 95%, or 96%, or 97% or 98% or 99% identical thereto, and, optionally, lacking SEQ ID NO: 14 or an amino acid sequence that is at least 90% identical to SEQ ID NO: 14.

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The protein of claim 1, comprising SEQ ID NO: 33 or a sequence at least 95%, or 96%, or 97% or 98% or 99% identical thereto, and, optionally, which lacks SEQ ID NO: 24 an amino acid sequence that is at least 90% identical to SEQ ID NO: 24.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The protein of claim 1 which: a) lacks SEQ ID NO: 23 or a sequence that is at least 90% identical to SEQ ID NO: 23 and/or lacks SEQ ID NO: 22 or a sequence that is at least 90% identical to SEQ ID NO: 22.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

The protein according to claim 1, wherein said protein comprises SEQ ID NO: 15 or a sequence at least 90% identical thereto and any one of SEQ ID NOs 4, 5, 25, 26 27, 29, 30, 32, or an amino acid sequence that is at least 90% identical to SEQ ID NO: 4, 5, 25, 26 27, 29, 30, or 32 wherein, compared to SEQ ID NO: 1, said protein comprises an internal deletion that is at least four consecutive amino acids long.

### Claim 30

(canceled)

### Claim 31 (depends on 1)

The protein according to claim 1 comprising SEQ ID NO: 11 or 12 or SEQ ID NO: 46 or a sequence that is at least 90%, or at least 91%, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%, or 100% identical to SEQ ID NO: 11 or SEQ ID NO: 12 or SEQ ID NO: 46.

### Claim 32

(canceled)

### Claim 33 (depends on 1)

A fusion protein comprising the protein of claim 1 and further comprising:
a) N-terminal secretion signal sequence of a secreted or a first membrane-bound protein upstream of the protein of claim 1;
b) a transmembrane domain of a second membrane-bound protein downstream of the protein of claim 1.

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36 (depends on 33)

The fusion protein of claim 33, wherein said N-terminal secretion signal sequence is at least 90% identical to SEQ ID NO: 7 or SEQ ID NO: 48, or wherein said secretion signal sequence comprises a portion of SEQ ID NO: 48 or a sequence at least 90% identical to SEQ ID NO: 48, wherein said portion comprises SEQ ID NO: 7 or a sequence that is at least 90% identical to SEQ ID NO: 7.

### Claim at position 26

-39. (canceled)

### Claim 40 (depends on 1)

A nucleic acid sequence that encodes the protein according to claim 1.

### Claim 41 (depends on 40)

The nucleic acid sequence according to claim 40, comprising SEQ ID NO: 16.

### Claim 42 (depends on 40)

A vector comprising the nucleic acid sequence according to claim 40.

### Claim 43 (depends on 42)

The vector of claim 42 further comprising a nucleic sequence encoding an immunomodulator.

### Claim 44

(canceled)

### Claim 45 (depends on 42)

The vector of claim 42 which is a plasmid vector.

### Claim 46 (depends on 42)

A host cell comprising the vector of claim 42.

### Claim 47 (depends on 42)

A vaccine comprising the vector of claim 42 or a vector comprising a nucleic acid sequence encoding SEQ ID NO: 1 or an amino acid sequence that is 98% identical thereto.

### Claim 48 (depends on 47)

A method of preventing piscine myocarditis virus (PMCV) infection in a salmonid in need thereof comprising administering to said salmonid the vaccine according to claim 47.

### Claim 49 (depends on 48)

The method of claim 48, wherein said salmonid weighs between 15 and 200 grams.

### Claim 50 (depends on 49)

The method of claim 49, wherein said salmonid weighs between 40 and 110 grams.

### Claim 51 (depends on 48)

The method of claim 48, wherein said salmonid is Atlantic salmon (Salmo salar), rainbow trout (Oncorhynchus mykiss), Chinook salmon (Oncorhynchus tshawytscha), or Coho Salmon (Oncorhynchus kisutch).

### Claim at position 39

-59. (canceled)
